MoonLake Immunotherapeutics (MLTX) Stock Price, News & Analysis

Company Overview

MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immunomodulatory therapies for autoimmune and inflammatory diseases. The company leverages a proprietary platform designed to selectively modulate key immune cell populations, aiming to restore immune balance and reduce tissue damage with targeted biologic candidates.

Its lead asset, MLTX101, is a recombinant immune cell modulator in clinical development for myositis, including inclusion body myositis and dermatomyositis. Early studies have shown promising results in enhancing immune regulation and diminishing muscle inflammation. MoonLake is conducting ongoing clinical trials to assess the safety, tolerability, and efficacy of MLTX101, while also advancing additional preclinical programs for other autoimmune and inflammatory indications.

Headquartered in the United States, MoonLake Immunotherapeutics collaborates with academic institutions, contract research organizations and industry partners to accelerate its research pipeline. The leadership team brings extensive expertise in immunology, drug development and regulatory affairs, guiding the company’s efforts to translate scientific innovation into patient-focused therapies. As a NASDAQ-listed company under the ticker MLTX, MoonLake continues to build strategic collaborations to support the growth of its clinical programs and expand its global reach.

Key Stats

• Today's Range: $9.34 to $10.59
• 50-Day Range: $6.24 to $61.99
• 52-Week Range: $5.95 to $62.75
• Volume: 9.47 million shs
• Average Volume: 1.56 million shs
• Market Capitalization: $659.00 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $36.00
• Consensus Rating: Hold

MoonLake Immunotherapeutics Stock Analysis - MarketRank™

MoonLake Immunotherapeutics scored higher than 57% of companies evaluated by MarketBeat, and ranked 455th out of 958 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.0 / 5
• Analyst Rating: Hold

Consensus Rating

MoonLake Immunotherapeutics has received a consensus rating of Hold. The company's average rating score is 2.07, and is based on 3 buy ratings, 9 hold ratings, and 2 sell ratings.

Upside Potential

MoonLake Immunotherapeutics has a consensus price target of $36.00, representing about 250.9% upside from its current price of $10.26.

Amount of Analyst Coverage

MoonLake Immunotherapeutics has been the subject of 14 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for MoonLake Immunotherapeutics are expected to decrease in the coming year, from ($1.79) to ($2.65) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of MoonLake Immunotherapeutics is -3.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of MoonLake Immunotherapeutics is -3.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

MoonLake Immunotherapeutics has a P/B Ratio of 1.45. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

8.98% of the float of MoonLake Immunotherapeutics has been sold short.

Short Interest Ratio / Days to Cover

MoonLake Immunotherapeutics has a short interest ratio ("days to cover") of 8.7.

Change versus previous month

Short interest in MoonLake Immunotherapeutics has recently decreased by 4.44%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

MoonLake Immunotherapeutics does not currently pay a dividend.

Dividend Growth

MoonLake Immunotherapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

8.98% of the float of MoonLake Immunotherapeutics has been sold short.

Short Interest Ratio / Days to Cover

MoonLake Immunotherapeutics has a short interest ratio ("days to cover") of 8.7.

Change versus previous month

Short interest in MoonLake Immunotherapeutics has recently decreased by 4.44%, indicating that investor sentiment is improving.

News and Social Media

• Score: 2.9 / 5
• News Sentiment: 0.15

News Sentiment

MoonLake Immunotherapeutics has a news sentiment score of 0.15. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.77 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 37 news articles for MoonLake Immunotherapeutics this week, compared to 7 articles on an average week.

Search Interest

73 people have searched for MLTX on MarketBeat in the last 30 days. This is an increase of 1,117% compared to the previous 30 days.

MarketBeat Follows

16 people have added MoonLake Immunotherapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 700% compared to the previous 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, MoonLake Immunotherapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $46,863,385.00 in company stock.

Percentage Held by Insiders

12.02% of the stock of MoonLake Immunotherapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

93.85% of the stock of MoonLake Immunotherapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

MLTX Stock Analysis - Frequently Asked Questions

How have MLTX shares performed this year?

MoonLake Immunotherapeutics' stock was trading at $54.15 at the start of the year. Since then, MLTX stock has decreased by 81.1% and is now trading at $10.26.

How were MoonLake Immunotherapeutics' earnings last quarter?

MoonLake Immunotherapeutics (NASDAQ:MLTX) announced its earnings results on Tuesday, August, 5th. The company reported ($0.87) EPS for the quarter, missing the consensus estimate of ($0.73) by $0.14.

How do I buy shares of MoonLake Immunotherapeutics?

Shares of MLTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of MoonLake Immunotherapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that MoonLake Immunotherapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), Disc Medicine (IRON), e.l.f. Beauty (ELF), Builders FirstSource (BLDR), Novo Nordisk A/S (NVO) and Arista Networks (ANET).

Company Calendar

• Last Earnings: 8/05/2025
• Today: 10/10/2025
• Next Earnings (Estimated): 11/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:MLTX
• CIK: 1821586
• Web: www.moonlaketx.com
• Phone: 41-41-510-8022
• Fax: N/A
• Employees: 2
• Year Founded: N/A

Price Target and Rating

• Average Price Target for MoonLake Immunotherapeutics: $36.00
• High Price Target: $100.00
• Low Price Target: $7.00
• Potential Upside/Downside: +250.9%
• Consensus Rating: Hold
• Rating Score (0-4): 2.07
• Research Coverage: 14 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.78)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$118.94 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -40.98%
• Return on Assets: -35.81%

Debt

• Debt-to-Equity Ratio: 0.21
• Current Ratio: 16.65
• Quick Ratio: 16.65

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $7.09 per share
• Price / Book: 1.45

Miscellaneous

• Outstanding Shares: 64,230,000
• Free Float: 56,510,000
• Market Cap: $659.00 million
• Optionable: Optionable
• Beta: 1.10